Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-624-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.37 million
Profitability
Miscellaneous
Employees137
OptionableOptionable
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics, Inc. (NASDAQ:CYTK) posted its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.11. The biopharmaceutical company earned $10.64 million during the quarter, compared to analysts' expectations of $2.23 million. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What price target have analysts set for CYTK?
5 Wall Street analysts have issued 1 year target prices for Cytokinetics' stock. Their predictions range from $10.00 to $21.00. On average, they anticipate Cytokinetics' share price to reach $13.80 in the next year. This suggests a possible upside of 79.7% from the stock's current price. View Analyst Price Targets for Cytokinetics.
What is the consensus analysts' recommendation for Cytokinetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.
What are Wall Street analysts saying about Cytokinetics stock?
Here are some recent quotes from research analysts about Cytokinetics stock:
- 1. HC Wainwright analysts commented, "Our thesis is based on three key areas at the company: (1) omecamtiv mecarbil program in heart failure with global partner Amgen (AMGN; not rated) and a projected significant boost in visibility this year (primary valuation contribution); (2) the volatile reldesmtiv program (ALS and SMA), which is expected to provide major answers this year; and (3)." (1/22/2019)
- 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (1/21/2019)
- 3. Cantor Fitzgerald analysts commented, "We have an Overweight rating based on ome’ in chronic HF and relde’ in SMA & ALS. For ome’, GALACTIC-HF data are expected in 2021, with interim reads in ’19 (futility) and ’20 (efficacy) that may lead to milestone payments to CYTK. Recent relde’ P2 data in SMA showed clinical benefit in 6MWD & MEP which enhances PoS in Type III SMA in our view. With VITALITY-ALS lessons learned & SMA PoC in hand, we are cautiously optimistic on relde’ prospects and believe investors may be overlooking potential value creation within the next 12 months." (12/5/2018)
Has Cytokinetics been receiving favorable news coverage?
Media stories about CYTK stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytokinetics earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include Myokardia (MYOK), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Opko Health (OPK), Pacira Pharmaceuticals (PCRX), Zai Lab (ZLAB), Theravance Biopharma (TBPH), Myovant Sciences (MYOV), Innoviva (INVA), Prestige Consumer Healthcare (PBH), Allakos (ALLK), Aimmune Therapeutics (AIMT), Uniqure (QURE), Nabriva Therapeutics (NBRV) and Corcept Therapeutics (CORT).
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.95%), Great Point Partners LLC (5.80%), Pinnacle Associates Ltd. (1.08%), Bank of New York Mellon Corp (1.08%), Geode Capital Management LLC (1.07%) and Northern Trust Corp (0.97%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.
Which major investors are selling Cytokinetics stock?
CYTK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pinnacle Associates Ltd., Dimensional Fund Advisors LP, Barclays PLC, Northern Trust Corp, Virtus ETF Advisers LLC, MetLife Investment Advisors LLC and United Services Automobile Association. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.
Which major investors are buying Cytokinetics stock?
CYTK stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Fosun International Ltd, Foresite Capital Management IV LLC, Citigroup Inc., ClariVest Asset Management LLC, Geode Capital Management LLC, D. E. Shaw & Co. Inc. and Bank of America Corp DE. View Insider Buying and Selling for Cytokinetics.
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $7.68.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $420.18 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.
What is Cytokinetics' official website?
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
